Photo of Monika Davare, Ph.D.

Monika Davare Ph.D.

  •      (503) 494-5056
    • Assistant Professor of Pediatrics, Division of Hematology and Oncology School of Medicine
    • Program in Molecular and Cellular Biosciences School of Medicine
    • Cancer Biology Graduate Program School of Medicine

The Davare laboratory’s research goals are directed towards overcoming the therapeutic bottleneck in rare but aggressive pediatric and adult cancers. Oncogenomics-driven big data approaches effectively identify lead drug targets for cancer, but bottlenecks arise from a lack or slower pace of functionally testing, vetting and optimizing leads for therapeutic development. Using complementary in vitro and in vivo experimental model systems coupled with patient-derived genomic data, we have successfully identified driving kinase pathways and validated small-molecule inhibitor therapies for targeting distinct genomic subsets of glioblastoma, sarcoma, medulloblastoma and non-small cell lung cancer. We have active cross-institutional collaborations with clinical oncologists to facilitate transfer of our bench discoveries into clinical trials and as needed, validate clinical findings back at the bench. I combine my expertise and experience in the areas of kinase biology, cell surface receptors, and ion channel physiology with my background in molecular pharmacology to lead this translational research program.


  • B.A., University of Maine (Zoology/Philosophy), Orono Maine 1995
  • Ph.D., University of Wisconsin-Madison (Molecular and Cellular Pharmacology), Madison Wisconsin 2000


  • "Rare but recurrent ROS1 fusions resulting from chromosome 6q22 microdeletions are targetable oncogenes in glioma." Clinical Cancer Research  In: , Vol. 24, No. 24, 15.12.2018, p. 6471-6482.
  • "Inhibition of interleukin-1 receptor-associated kinase-1 is a therapeutic strategy for acute myeloid leukemia subtypes." Leukemia  In: , 29.03.2018, p. 1-14.
  • "Insulin-like growth factor 1 receptor stabilizes the ETV6-NTRK3 chimeric oncoprotein by blocking its KPC1/Rnf123-mediated proteasomal degradation." Journal of Biological Chemistry  In: , Vol. 293, No. 32, 01.01.2018, p. 12502-12515.
  • "Functional validation of the oncogenic cooperativity and targeting potential of tuberous sclerosis mutation in medulloblastoma using a MYC-amplified model cell line." Pediatric Blood and Cancer  In: , 2017.
  • "IGF1R as a Key Target in High Risk, Metastatic Medulloblastoma." Scientific Reports  In: , Vol. 6, 27012, 03.06.2016.
  • "A novel crizotinib-resistant solvent-front mutation responsive to cabozantinib therapy in a patient with ROS1-rearranged lung cancer." Clinical Cancer Research  In: , Vol. 22, No. 10, 15.05.2016, p. 2351-2358.
  • "Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors." Proceedings of the National Academy of Sciences of the United States of America  In: , Vol. 112, No. 39, 29.09.2015, p. E5381-E5390.
  • "Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia." Oncogene  In: , Vol. 34, No. 23, 04.06.2015, p. 2991-2999.
  • "Therapeutically targetable ALK mutations in leukemia." Cancer Research  In: , Vol. 75, No. 11, 01.06.2015, p. 2146-2150.
  • "Detecting and targetting oncogenic fusion proteins in the genomic era." Biology of the Cell  In: , Vol. 107, No. 5, 01.05.2015, p. 111-129.
  • "Small molecule inhibitor screen identifies synergistic activity of the bromodomain inhibitor CPI203 and bortezomib in drug resistant myeloma." Oncotarget  In: , Vol. 6, No. 22, 2015, p. 18921-18932.
  • "Secreted meningeal chemokines, but not VEGFA, modulate the migratory properties of medulloblastoma cells." Biochemical and Biophysical Research Communications  In: , Vol. 450, No. 1, 18.07.2014, p. 555-560.
  • "Leptin-induced spine formation requires TrpC channels and the CaM kinase cascade in the hippocampus." Journal of Neuroscience  In: , Vol. 34, No. 30, 2014, p. 10022-10033.
  • "Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins." Proceedings of the National Academy of Sciences of the United States of America  In: , Vol. 110, No. 48, 26.11.2013, p. 19519-19524.
  • "Mouse model of intrahepatic cholangiocarcinoma validates FIG-ROS as a potent fusion oncogene and therapeutic target." Proceedings of the National Academy of Sciences of the United States of America  In: , Vol. 110, No. 48, 26.11.2013, p. 19513-19518.
  • "A Genome-Wide Screen of CREB Occupancy Identifies the RhoA Inhibitors Par6C and Rnd3 as Regulators of BDNF-Induced Synaptogenesis." PLoS One  In: , Vol. 8, No. 6, e64658, 06.06.2013.
  • "Preclinical testing of tandutinib in a transgenic medulloblastoma mouse model." Journal of Pediatric Hematology/Oncology  In: , Vol. 34, No. 2, 03.2012, p. 116-121.
  • "Corrigendum to "An activity-induced microRNA controls dendritic spine formation by regulating Rac1-PAK signaling" [YMCNE (2010) 146-156]." Molecular and Cellular Neuroscience  In: , Vol. 49, No. 2, 02.2012, p. 250.
  • "Bortezomib stabilizes NOXA and triggers ROS-associated apoptosis in medulloblastoma." Journal of Neuro-Oncology  In: , Vol. 105, No. 3, 12.2011, p. 475-483.
  • "Calmodulin-kinases regulate basal and estrogen stimulated medulloblastoma migration via Rac1." Journal of Neuro-Oncology  In: , Vol. 104, No. 1, 08.2011, p. 65-82.
  • "Analysis of CaM-kinase signaling in cells." Cell Calcium  In: , Vol. 50, No. 1, 07.2011, p. 1-8.
  • "Long-term potentiation-dependent spine enlargement requires synaptic Ca2+-permeable AMPA receptors recruited by CaM-kinase I." Journal of Neuroscience  In: , Vol. 30, No. 35, 01.09.2010, p. 11565-11575.
  • "ERK activation and cell growth require CaM kinases in MCF-7 breast cancer cells." Molecular and Cellular Biochemistry  In: , Vol. 335, No. 1-2, 02.2010, p. 155-171.
  • "An activity-induced microRNA controls dendritic spine formation by regulating Rac1-PAK signaling." Molecular and Cellular Neuroscience  In: , Vol. 43, No. 1, 01.2010, p. 146-156.
  • "Transient receptor potential canonical 5 channels activate Ca 2+/calmodulin kinase Iγ to promote axon formation in hippocampal neurons." Journal of Neuroscience  In: , Vol. 29, No. 31, 05.08.2009, p. 9794-9808.
  • "Statins decrease dendritic arborization in rat sympathetic neurons by blocking RhoA activation." Journal of Neurochemistry  In: , Vol. 108, No. 4, 02.2009, p. 1057-1071.
  • "An activity-regulated microRNA controls dendritic plasticity by down-regulating p250GAP." Proceedings of the National Academy of Sciences of the United States of America  In: , Vol. 105, No. 26, 01.07.2008, p. 9093-9098.
  • "Activity-Dependent Synaptogenesis : Regulation by a CaM-Kinase Kinase/CaM-Kinase I/βPIX Signaling Complex." Neuron  In: , Vol. 57, No. 1, 10.01.2008, p. 94-107.
  • "Critical role of cAMP-dependent protein kinase anchoring to the L-type calcium channel Cav1.2 via A-kinase anchor protein 150 in neurons." Biochemistry  In: , Vol. 46, No. 6, 13.02.2007, p. 1635-1646.
  • "Bidirectional regulation of cytoplasmic polyadenylation element-binding protein phosphorylation by Ca/calmodulin-dependent protein kinase II and protein phosphatase 1 during hippocampal long-term potentiation." Journal of Neuroscience  In: , Vol. 25, No. 23, 08.06.2005, p. 5604-5610.

Additional information

Edit profile